Immunoreactivity of MAP-2 has been demonstrated in most neuroendocrine and neuroectodermal related neoplasms such as small cell carcinoma, large cell neuroendocrine carcinoma, carcinoid tumor of the lung, Merkel cell carcinoma of the skin, medulloblastoma, neurocytoma of the central nervous system, extrapulmonary small cell carcinoma and carcinoid tumor, and malignant melanomas.